As Brexit row becomes increasingly anarchic, is UK’s reputation with pharma suffering?The political crisis surrounding Brexit shows little sign of ending after the tumultuous events of this week. Paul Share XAs Brexit row becomes increasingly anarchic, is UK’s reputation with pharma suffering?https://pharmaphorum.com/views-analysis-market-access/brexit-row-anarchic-pharma/
Keeping up the PACE at the Scottish Medicines Consortium (SMC)There are many ways that patient centricity could be delivered when doing a health technology assessment (HTA). The Share XKeeping up the PACE at the Scottish Medicines Consortium (SMC)https://pharmaphorum.com/views-analysis-market-access/keeping-up-the-pace-at-the-scottish-medicines-consortium-smc/
Market access roundup: Government grillings for Vertex and US pharmaIt was a month characterised by governments butting heads with pharma over pricing both in the UK and Share XMarket access roundup: Government grillings for Vertex and US pharmahttps://pharmaphorum.com/views-analysis-market-access/market-access-roundup-government-grillings-vertex-us-pharma-pricing/
The great regulatory catch-upMedical device manufacturers have a lot to learn from the pharmaceutical sector which, for well over a decade, Share XThe great regulatory catch-uphttps://pharmaphorum.com/views-analysis-market-access/great-regulatory-medical-device/
The shadow of Brexit on speed of accessNo-one can miss the ongoing saga that is the UK’s exit from the European Union (EU). The uncertainties Share XThe shadow of Brexit on speed of accesshttps://pharmaphorum.com/views-analysis-market-access/the-shadow-of-brexit-on-speed-of-access/
Rare Disease Day: How the patient voice can tear down barriersTo have any impact, patient engagement needs to start with the drug development pathway, not at the point Share XRare Disease Day: How the patient voice can tear down barriershttps://pharmaphorum.com/views-and-analysis/rare-disease-day-how-the-patient-voice-can-tear-down-barriers/
Market access roundup: UK HTA shakeups as Brexit fears deepenWith a Brexit deal still out of sight, there have been intensified warnings in the UK about potential Share XMarket access roundup: UK HTA shakeups as Brexit fears deepenhttps://pharmaphorum.com/views-and-analysis/market-access-roundup-uk-hta-shakeups-as-brexit-fears-deepen/
Biotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?Drug development can be quite a risky business at the best of times, but particularly in the biotech Share XBiotech in post-Brexit Britain: the future for the UK’s pharma-innovation engine?https://pharmaphorum.com/views-and-analysis/biotech-in-post-brexit-britain-the-future-for-the-uks-pharma-innovation-engine/
Access to new medicines in Scotland: a perennial issueAccess to new medicines in Scotland – just as it would seem is the case everywhere – is Share XAccess to new medicines in Scotland: a perennial issuehttps://pharmaphorum.com/views-and-analysis/access-to-new-medicines-in-scotland-a-perennial-issue/
